Focus: Merit Medical is a mid-cap medical device company with 5,000+ employees generating $1.3B in revenue across multiple therapeutic areas including cardiovascular, nephrology, oncology, and neurology. The company is publicly traded (MMSI) and operates a diversified portfolio of minimally invasive medical devices.
Profile data last refreshed 12h ago · AI intelligence enriched 1w ago
Hot — 207 jobs added in 30d
Net +158 (207 new, 49 removed). Aggressive expansion phase.
Merit Medical is a stable, growth-stage medical device company suited for professionals prioritizing operational execution and commercial scaling over early-stage innovation.
Help build intelligence for Merit Medical
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Merit Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
World Carbon Dioxide Contrast Agents - Market Analysis, Forecast, Size, Trends and Insights - IndexBox
World Carbon Dioxide Contrast Agents - Market Analysis, Forecast, Size, Trends and Insights IndexBox
Here's why you should retain Merit Medical stock in your portfolio now - MSN
Here's why you should retain Merit Medical stock in your portfolio now MSN
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now - TradingView
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now TradingView
Drug-Eluting Beads Market Forecast Points Higher Toward 2035, Driven by Rising HCC Incidence and Minimally Invasive Procedure Adoption - IndexBox
Drug-Eluting Beads Market Forecast Points Higher Toward 2035, Driven by Rising HCC Incidence and Minimally Invasive Procedure Adoption IndexBox
8-K Filing: Medtronic plc (MDT) (CIK 0001613103) — EX-99.1
EX-99.1
Q1 2026 Life Sciences Earnings Review: PacBio vs. West Pharmaceutical Performance - News and Statistics - IndexBox
Q1 2026 Life Sciences Earnings Review: PacBio vs. West Pharmaceutical Performance - News and Statistics IndexBox
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Patency rates following treatment with the WRAPSODY™ Cell-Impermeable Endoprosthesis for recalcitrant renal access circuit dysfunction: Results from a tertiary Australian centre.
Objective Performance Goals Based on a Systematic Review and Meta-Analysis of Clinical Outcomes for Bare-Metal Stents and Percutaneous Transluminal Angioplasty for Hemodialysis-Related Central Venous Obstruction.
Showing 5 of 7 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo